A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting

Phase 2

Phase 3

Nivolumab & IpilimumabA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT02339571

Conditions

Stage III Cutaneous Melanoma AJCC v7

Stage IV Cutaneous Melanoma AJCC v6 and v7

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Echocardiography Test

Ipilimumab

Magnetic Resonance Elastography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-29.